#ASGCT26: Tessera reveals strongest data yet for in vivo sickle cell therapy
BOSTON — Tessera Therapeutics has created an experimental gene editing drug for sickle cell disease that could compete with commercial cell therapies but is delivered as an infusion — no complex cell engineering or chemotherapy preconditioning ...
May 13, 2026 08:00 AM EDT R&DCell/Gene Tx Tessera says infusion edits 85% of blood cells, pointing to off-the-shelf sickle cell fix Ryan Cross Senior Science Correspondent BOSTON — Tessera Therapeutics has created an experimental gene editing drug for sickle cell disease that could compete with commercial cell therapies but is delivered … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER
comments(0)
5-min edit window · permanent after that